Clinical Trials Logo

Bacterial Pneumonia clinical trials

View clinical trials related to Bacterial Pneumonia.

Filter by:

NCT ID: NCT00107952 Completed - Bacterial Pneumonia Clinical Trials

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

ATTAIN1
Start date: February 2005
Phase: Phase 3
Study type: Interventional

Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

NCT ID: NCT00081575 Completed - Bacterial Pneumonia Clinical Trials

Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

Start date: January 2004
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

NCT ID: NCT00080496 Completed - Bacterial Pneumonia Clinical Trials

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

Start date: July 2003
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.

NCT ID: NCT00079885 Completed - Clinical trials for Community Acquired Pneumonia

Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia

Start date: November 2003
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the study will be the clinical response in the clinically evaluable population and the clinical response in the clinical modified intent-to-treat population at the TOC visit. The primary efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If tigecycline is found to be noninferior, the analyses will determine whether tigecycline is statistically better than levofloxacin.